Trevena (NASDAQ:
TRVN)
40% HIGHER; announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery. The study achieved its primary endpoint of statistically greater pain reduction than placebo over 24 hours. In addition, TRV130 was superior to morphine in pre-specified secondary measures, exhibiting significantly reduced nausea, vomiting, and hypoventilation events.
Adept Technology (NASDAQ:
ADEP)
7.8% LOWER; reported Q4 EPS of ($0.10), $0.03 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $13.9 million versus the consensus estimate of $14.4 million.
Matrix Service (NASDAQ:
MTRX)
6.8% LOWER; reported Q4 EPS of $0.40, $0.13 better than the analyst estimate of $0.27. Revenue for the quarter came in at $370.5 million versus the consensus estimate of $378.45 million. Matrix Service sees FY2016 EPS of $1.45-$1.75, versus the consensus of $1.58. Matrix Service sees FY2016 revenue of $1.4-1.6 billion, versus the consensus of $1.50 billion.
SunEdison (NYSE:
SUNE)
4% HIGHER; In a 13G filing on SunEdison (NYSE:
SUNE), Steven Cohen's family office Point72 Asset Management, L.P. disclosed a 5.1%, or 15,954,818 share, stake in the company. This is up 621.19% from the 2,212,300 shares held at the end of the latest quarter ending June 30, 2015.
No comments:
Post a Comment